ENBIO Past Earnings Performance
Past criteria checks 0/6
ENBIO's earnings have been declining at an average annual rate of -43.1%, while the Chemicals industry saw earnings growing at 5.1% annually. Revenues have been declining at an average rate of 1% per year.
Key information
-43.1%
Earnings growth rate
-45.6%
EPS growth rate
| Chemicals Industry Growth | 13.9% |
| Revenue growth rate | -1.0% |
| Return on equity | -7.4% |
| Net Margin | -9.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How ENBIO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 35,037 | -3,212 | 9,122 | 578 |
| 30 Jun 24 | 33,506 | -4,262 | 9,041 | 578 |
| 31 Mar 24 | 29,419 | -8,701 | 9,230 | 578 |
| 31 Dec 23 | 34,024 | -6,300 | 9,199 | 578 |
| 30 Sep 23 | 33,887 | -3,864 | 8,338 | 524 |
| 30 Jun 23 | 37,882 | -2,564 | 8,906 | 524 |
| 31 Mar 23 | 34,180 | -2,307 | 9,703 | 394 |
| 31 Dec 22 | 34,240 | -3,445 | 8,882 | 524 |
| 30 Sep 22 | 35,645 | -254 | 8,935 | 84 |
| 30 Jun 22 | 31,234 | -1,118 | 8,243 | 194 |
| 31 Mar 22 | 38,405 | 2,447 | 7,692 | 517 |
| 31 Dec 21 | 33,466 | 5,245 | 7,467 | 388 |
| 30 Sep 21 | 35,436 | -1,112 | 7,862 | 773 |
| 30 Jun 21 | 34,623 | -1,424 | 8,343 | 663 |
| 31 Mar 21 | 34,404 | -2,780 | 7,475 | 469 |
| 31 Dec 20 | 34,563 | -4,449 | 8,110 | 469 |
| 30 Sep 20 | 36,717 | 1,411 | 7,396 | 450 |
| 31 Dec 19 | 33,736 | 1,020 | 6,229 | 450 |
| 31 Dec 18 | 30,328 | -8,094 | 7,140 | 624 |
| 31 Dec 17 | 30,441 | 890 | 6,462 | 575 |
| 31 Dec 16 | 28,803 | 859 | 6,693 | 667 |
| 31 Dec 15 | 24,526 | 1,694 | 5,322 | 572 |
| 31 Dec 14 | 24,422 | 2,248 | 4,772 | 502 |
| 31 Dec 13 | 21,468 | 1,876 | 3,758 | 266 |
Quality Earnings: A352940 is currently unprofitable.
Growing Profit Margin: A352940 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A352940 is unprofitable, and losses have increased over the past 5 years at a rate of 43.1% per year.
Accelerating Growth: Unable to compare A352940's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A352940 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (19.6%).
Return on Equity
High ROE: A352940 has a negative Return on Equity (-7.43%), as it is currently unprofitable.